Idéal Investisseur Connexion Connexion
Français English
CAC 40 : Market open
8 137,78 pts
-0.11%


Last updated : 19/11/2026 - 15h35
🏠 Home   ➤    Stock news

DBV Technologies shares drop 16.5% over the week despite a rebound

The Châtillon-based biotech recovers in mid-afternoon, while the SBF 120 is slightly negative. This rebound follows several sessions of decline, as its US marketing authorization application continues and its financial position remains under close watch.


DBV Technologies shares drop 16.5% over the week despite a rebound

A rebound that leaves the stock below its three moving averages

The stock gains 1.71% to €1.78, among the strongest gainers of the SBF 120, while the index falls 0.15%. The move remains modest compared with the 16.59% decline recorded over the week, even though DBV Technologies still shows +13.52% over one month.

The price is below the MA20 (€1.84, a gap of 3.26%) and the MA50 (€1.88), while the MA200 at €2.79 is far away, more than 36% above the price.

The RSI at 46 signals neither overbought nor oversold conditions, and the support at €1.57 remains at a good distance. In recent days, the stock had been trading at the bottom of the index, as at the beginning of the week.

An open FDA file and a financing horizon to watch

When the 9M 2026 accounts were published on October 28, 2026, the company reported substantial doubt about its ability to continue as a going concern over twelve months, and a need for additional capital beyond the third quarter of 2027.

Among the opportunities mentioned on that occasion was the filing of the marketing authorization application for the Viaskin Peanut patch in children aged 4 to 7, with an FDA decision expected in the fourth quarter of 2026.

Furthermore, according to the declarations consulted, five funds together hold 3.59% of the capital sold short, up 0.70 points over one month. This is a high level, reflecting a non-negligible bearish positioning, although the intentions of the market participants cannot be inferred from it. The resistance level at €2.13 is the next level identified in the data.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Biotechnologies


Context

Period
  • Period: 9M 2026
Key reported figures
  • Revenue: 3,1 millions de dollars
  • Quarterly revenue: 3,1 millions de dollars
  • Revenue growth: -38 %
  • Net income: -162,5 millions de dollars
  • Free cash flow: -159,4 millions de dollars
Risks mentioned
  • Substantial doubt exists about the Company's ability to continue as a going concern within twelve months
  • Manufacturing remediation activities ongoing at Fareva following FDA Warning Letter of April 2026
  • Company requires additional capital to fund operations beyond Q3 2027
Opportunities identified
  • BLA for VIASKIN Peanut Patch in children aged 4-7 years submitted with Priority Review requested, expected FDA determination in Q4 2026
  • Planned BLA submission for toddlers aged 1-3 years in 2027 with potential rolling submission approach
  • Recent $50 million ADS financing completed and $150 million ATM program refreshed to support operations and commercial readiness

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours